Summary
Indications and types of adjuvant treatment depend on the number of infiltrated axillary lymph nodes, menopausal and hormonal receptor status. In N0 situation is to date no indication for hormonal or cytotoxic therapy outside of clinical trials: disease-free survival may be improved but overall survival is not influenced. In N+ situation premenopausal patients should receive polychemotherapy independent from hormonal receptor status, postmenopausal patients with positive receptor status should be treated with tamoxifen up to 5 years: in this situation disease-free intervall and overall survival can be enhanced significantly.
Zusammenfassung
Indikationen und Behandlungsmodalitäten hängen bei der adjuvanten Therapie der Mammakarzinome von der Anzahl infiltrierter Lymphknoten (Lk), dem Menopausen- und dem Hormonrezeptorstatus ab. Bei fehlendem Lk-Befall ist derzeit außerhalb von Therpiestudien keine Behandlungsindikation gegeben. Bei Befall der axillären Lymphknoten sollten prämenopausale Patientinnen unabhängig vom Hormonrezeptorstatus eine Polychemotherapie, postmenopausale Patientinnen mit positivem Rezeptorstatus eine mehrjährige Behandlung mit Tamoxifen erhalten.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bonadonna G, Valagussa P (1988) Adjuvant chemotherapy for breast cancer. Sem Surg Oncol 4:250–255
Consensus Conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254:3461–3463
Multidisziplinäre Konsensus-Tagung, Brusterhaltende Therapie beim Mammakarzinom. Indikationen und Konsequenzen. Dtsch Ärzteblatt (1990) im Druck
Clinical Alert on breast cancer, National Cancer Institute, PDQ News, May 18 (1988)
Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C (1989) A randomiced clinical trial evaluating sequential methotrexate, and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473–478
Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G (1989) Efficacy of adjuvant chemotherapy in high-risk-node-negative breast cancer. An intergroup study. N Engl J Med 320:485–490
Fisher B, Costantino C, Redmont C, Poisson R, Bowman D, Conture J, Dimitrov NW, Wolmark N, Wickerham DL, Fisher ER (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–478
Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N (1989) Adjuvant tamoxifen in early breast cancer: occurence of new primary cancers. Lancet I:117–120
Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunei M (1989) Prognostic value of estrogen and progesteron receptors in primary infiltrating ductal breast cancer, a sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol 25:1233–1240
Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G (1989) Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165–1171
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627–633
Burki F, Ginsbourg M, Hellbardt A, Misset JL, Musset M, Despax R, Goldschmidt E, Ribaud P, Mathe G (1988) Screening for micrometastases in the bone marrow of breast cancer patients, prognostic value and correlation with other prognostic factors. 2nd Int. Congress on Neo-Adjuvant Chemotherapy, p 15
Bonadonna G (1985) Results of the Milan adjuvant chemotherapy trials. NHI Consensus Development Conference, Washington, Book of Abstracts p 31
Davidson NE, Lippman ME (1988) Adjuvant therapy for breast cancer. Diagnosis and Management of Breast Cancer. In: Lippmann ME et al. (eds) Saunders, Philadelphia, p 348–374
Jordan VC, Tormey DC (1988) Antiestrogen therapy for breast cancer, current strategies and future prospects. Cancer Treat Rep 39:97–110
Stewart HJ, White GK (1988) Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. 3rd International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Switzerland, p 13
Goldhirsch A, Gelber RD (1988) Chemo-endocrine Therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV. 3rd International Conference on Adjuvant Therapy of Primary Breast Cancer. St. Gallen, Switzerland, p 16
Taylor SG, Knuiman MW, Sleeper LA, Olson JE, Tormey DC, Gilchrist KW, Falkson G, Rosenthal SN, Carbone PP, Cummings FJ (1989) Six-years results of Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 7:879–889
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Possinger, K. (1990). Mammakarzinom: Adjuvante Hormon- und Chemotherapie. In: Ungeheuer, E. (eds) Deutsche Gesellschaft für Chirurgie. Langenbecks Archiv für Chirurgie Gegründet 1860 Kongreßorgan der Deutschen Gesellschaft für Chirurgie, vol 1990. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-48163-5_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-48163-5_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-52926-2
Online ISBN: 978-3-642-48163-5
eBook Packages: Springer Book Archive